Fuji Xerox Co., Ltd.

Riken Corporation

Kyushu Institute of Technology

Takeda Chemical Industries, Inc.

Astellas Pharma Gmbh

Japan Science and Technology Corporation

Shin-etsu Polymer Co., Ltd.

Sumitomo Pharmaceuticals Company Limited

Japan Energy Corporation

Toray Industries, Inc.

Minoru Yoshida

Kazuyuki Tsukamoto

Norikazu Nishino

Naoki Suto

Manabu Hayashi

Takashi Sakayama

Tsuyoshi Watanabe

Hideki Fujii

Sadayuki Kobayashi

Sueharu Horinouchi

Ryuji Hosaka

Tomoo Fukao

Naoharu Kido

Toshitaka Nakagawa

Yuichi Shiho

Hitoshi Tamura

Yasuhiko Komatsu

Toshiyu Ishikawa

Satoshi Watanabe

Isao Tanaka

Hirotaka Kawabata

Akito Tanaka

Kazunori Nishi

Yoshiaki Tezuka

Tsutomu Mimoto

Isao Manabe

Ryosuke Matsui

Yutaka Uehara

Taiji Yamamoto

Hidenori Nakajima

Nobuyuki Oobayashi

Nobuyuki Kudo

Hajime Tsujihana

Nobuyasu Noda

Masayuki Honda

Junichi Nakagawa

Naoharu Kodo

A modem transmission level and modem sensitivity which are communication control information corresponding to the connection form of each destination device are registered in advance in a destination information storage unit so as to be correlated with an abbreviated dialing number of the destination. When a communication instruction using an abbreviated dialing number is received, if a modem transmission level and modem sensitivity are registered in the destination information storage unit as corresponding to the received abbreviated dialing number, the modem is controlled based on those registered modem transmission level and modem sensitivity. If neither a modem transmission level or modem sensitivity is registered as corresponding to the received abbreviated dialing number, the modem is controlled according to a modem transmission level and modem sensitivity that are registered in advance in the apparatus.

Image communication apparatus with transmission control

An image communication apparatus includes an unit for obtaining a threshold value that determines a coding format used for transmission of an image stored for the transmission from an information of the image stored for the transmission; and a transmission controlling unit that transmits the image stored for the transmission using a JBIG format if a size of the image stored for the transmission exceeds the threshold value, and transmits the image using a coding format having a compression ratio lower than that of the JBIG format if the size of the image stored for the transmission does not exceed the threshold value.

Image communication apparatus and computer readable medium for controlling image communication

An image information transmission device includes a registration unit, a storage unit, a determination unit, and an image information transmission unit. The registration unit registers an image information transmission instruction describing a destination number specifying a destination of image information and an abbreviated number corresponding to the destination number. The storage unit stores the destination number and transmission setting information used for transmitting the image information to the destination specified by the destination number. The determination unit determines whether or not the destination number described in the image information transmission instruction is contained in the destination number. The image information transmission unit transmits the image information.

Image information transmission device, image information transmission method and computer readable medium

A novel compound having histone deacetylase-inhibiting activity which is a cyclic tetrapeptide derivative represented by the general formula (1) given below and a pharmaceutical composition comprising such compound as an active ingredient. (In the formula, the cyclic tetrapeptide moiety has a known structure; Rand Reach independently represents an alkylene group containing 1 to 6 carbon atoms, which may be branched; X represents a group or bond selected from among &#x2014;CO&#x2014;, &#x2014;O&#x2014;, &#x2014;S&#x2014; or &#x2014;SO&#x2014;; Y represents a hydrogen or halogen atom, a phenyl group (including a substituted form), a pyridyl group (including a substituted form), an alkyl group (including a halogen-substituted form; hereinafter the same shall apply) containing 1 to 6 carbon atoms, an alkyloxy group containing 1 to 6 carbon atoms, an alkylcarbonyl group containing 1 to 6 carbon atoms, an alkyloxycarbonyl group containing 1 to 6 carbon atoms, an alkylthio group containing 1 to 6 carbon atoms, an alkylthiocarbonyl group containing 1 to 6 carbon atoms or a mono- or dialkylamino group containing 1 to 6 carbon atoms; when Y is a phenyl group (including a substituted form) or a pyridyl group (including a substituted form), it may form a further cyclic structure bound to R.) 

Compound having histone deacetylase-inhibiting activity, and pharmaceutical composition comprising the compound as an active ingredient

A weatherstrip composition includes the following polymer A group and polymer B group, Polymer A group. A polymer group is made up of a domainconsisting of crosslinked product of a polymer selected from a group consisting of ethylene polymer, ethylene/&#x3b1;-olefin copolymer (where the &#x3b1;-olefin has from 3 to 20 carbons), ethylene/&#x3b1;-olefin/diene copolymer (where the .alpha.-olefin has from 3 to 20 carbons), homopolymer rubber of a conjugated diene monomer, copolymer polymerized with a conjugated diene monomer and an aromatic vinyl monomer, and hydrogenated copolymer polymerized with a conjugated diene monomer and an aromatic vinyl monomer (where the hydrogenation of all double bonds except for the aromatic groups is at least 50%), and a domainis made up of crosslinked product of ethylene polymer or ethylene/&#x3b1;-olefin copolymer (where the &#x3b1;-olefin has from 3 to 20 carbons).

Weatherstrip

HDAC inhibitor of the general formula (1) exhibits strong inhibitory activity against various subtype HDACs. The compound is useful as a medicinal agent for the treatment or prevention of HDAC 1, 4 and 6-related diseases. There is further provided a process for producing the compound which is capable of readily synthesizing various types of compounds and is promising in the contribution to the development of HDAC inhibitor having novel properties, etc.

Histone deacetylase inhibitor and process for producing the same

Compounds represented by formula (1) have strong inhibitory activity that is selective towards HDAC1 and HDAC4. Therefore, the compounds of the present invention are useful as pharmaceutical agents for treating or preventing diseases caused by HDAC1 and HDAC4. 

Histone deacetylase inhibitors and methods for producing the same

An image processing apparatus for processing image data comprises a printer for printing processed image data on recording paper; an image data receiver for receiving image data transmitted thereto via a network; storage unit for storing the image data received by the image receiver; a print controller for controlling printing of the image data stored in the storage unit on the recording paper; and one or more feed trays that load recording paper loaded therein and feed the loaded recording paper to the printer, wherein, if recording paper of the image data is larger in size than any recording paper loaded in the feed trays, the print controller reduces in size image data to fit with largest-size recording paper of the recording paper loaded in the feed trays, and prints the size-reduced image data on the largest-size paper.

Image processing apparatus and print control method therefor

An image formation apparatus, such as a facsimile machine, outputs a received document (image) in the form of a print. The image formation apparatus includes a receive section and an image formation section. The receive section receives an electronic mail and an attached document thereof over a network. The image formation section forms images of a main body of the electronic mail and the attached document. The images of the main body and the attached document are formed on separate sheets respectively.

Image formation method and apparatus

An image formation apparatus which has multiple paper feed units and performs plural types of processing including at least facsimile processing, comprising a paper feeding subject setting unit which sets availability of paper feeding of each of the paper feed units when at least the facsimile processing is performed; and a warning unit which issues a warning when all the paper feed units are excluded from paper feeding at the time of the facsimile processing as a result of setting by the paper feeding subject setting unit.

Image formation apparatus and paper feed control method therefor

Anti-acetyllysine monoclonal antibody capable of recognizing N-acetyllysine regardless of the types of the adjacent amino acids. Namely, a monoclonal antibody having a light chain comprising a constant region having the amino acid sequence represented by SEQ ID NO:1 and a variable region having the amino acid sequence represented by SEQ ID NO:2 or an amino acid sequence derived from this amino acid sequence by deletion, substitution or addition of one to several amino acids, and a heavy chain comprising a constant region having the amino acid sequence represented by SEQ ID NO:3 and a variable region having the amino acid sequence represented by SEQ ID NO:4 or an amino acid sequence derived from this amino acid sequence by deletion, substitution or addition of one to several amino acids, and being capable of recognizing N-acetyllysine in a protein regardless of the types of the adjacent amino acids, i.e., being capable of accepting adjacent amino acids over a broad range; and a process for producing this monoclonal antibody characterized by using a chemically acetylated protein as an antigen.

Acetyllysine-recognizing monoclonal antibody and process for producing the same

The present invention relates to reduced FK228 of the formula (I) wherein Rand Rare the same or different and each is a hydrogen atom or a thiol-protecting group, or a salt thereof, and a histone deacetylase inhibitor containing this compound, an expression potentiator and a reactivation promoter of a transgene, and pharmaceutical agents containing them as active ingredients. The reduced FK228 or a salt thereof has a strong histone deacetylase inhibitory activity and this compound can be used for the prophylaxis or treatment of various diseases, in which histone deacetylation is involved, and for the gene therapy of such diseases.

Reduced FK228 and use thereof

Cyclic tetrapeptide derivatives and pharmaceutical uses thereof

Cyclic tetrapeptide derivatives and medicinal use thereof

A protein which comprises the sane or substantially the same amino acid sequence as that represented by SEQ ID NO:1, its partial peptide and their salts are disclosed. DNA encoding the protein or its partial peptide is also disclosed. The protein, its partial peptide or a salt thereof is an inhibitory factor of a transcription factor and, therefore, it is useful as medicine such as prophylactic and therapeutic drugs of, for example, tumors. The DNA is useful as a gene diagnosing drug. The antibody against the protein, etc. is also disclosed. The antibody is used for, for example, quantitative determination of the protein, etc. in a specimen fluid. The protein, etc. are also useful as a reagent for screening for compounds or their salts which promote the function of the protein, etc.

Human CRM1 Protein

Growing community of inventors

Saitama, Japan

Minoru Yoshida